Prelude Therapeutics director granted 38,000 stock options
Prelude Therapeutics Inc director Paul A. Friedman received a grant of stock options as part of his board compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Prelude Therapeutics Inc director Paul A. Friedman received a grant of stock options as part of his board compensation. The award covers 38,000 options to buy common stock at an exercise price of $3.94 per share and expires on June 8, 2036. The options will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided he continues serving the company through the vesting date.
Insider Trade Summary
Grant/Award: 38,000 shares
Grant/Award
1 txn
Insider
FRIEDMAN PAUL A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 38,000 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 38,000 contracts (Direct)
Footnotes (1)
- F1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Key Figures
Options granted: 38,000 options
Exercise price: $3.94 per share
Expiration date: June 8, 2036
+1 more
4 metrics
Options granted
38,000 options
Director stock option award to Paul A. Friedman
Exercise price
$3.94 per share
Exercise price for the 38,000 director stock options
Expiration date
June 8, 2036
Option term for director stock option grant
Shares underlying options
38,000 shares
Common stock underlying the director stock option grant
Key Terms
Director Stock Option (Right to Buy), exercise price, expiration date, annual stockholder meeting
4 terms
Director Stock Option (Right to Buy) financial
"security_title: "Director Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "3.9400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual stockholder meeting financial
"the Issuer's next annual stockholder meeting, or (b) the one-year anniversary"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Prelude Therapeutics (PRLD) director Paul A. Friedman report on this Form 4?
Paul A. Friedman reported receiving a grant of stock options for 38,000 shares of Prelude Therapeutics common stock. These options are part of his director compensation and give him the right to buy shares at a fixed exercise price in the future.
How many Prelude Therapeutics (PRLD) options were granted to Paul A. Friedman?
He was granted stock options covering 38,000 shares of Prelude Therapeutics common stock. This entire amount is newly awarded in this transaction and represents his total option holdings related to this grant after the reported award.
What is the exercise price of Paul A. Friedman’s Prelude Therapeutics (PRLD) stock options?
The stock options have an exercise price of $3.94 per share. This means Friedman can purchase Prelude Therapeutics common stock at $3.94 per share once the options are vested and exercised, regardless of the market price at that time.
When do Paul A. Friedman’s Prelude Therapeutics (PRLD) options vest?
The options will fully vest on the earlier of Prelude Therapeutics’ next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditioned on Friedman continuing to provide services to the company through the applicable vesting date.
When do Paul A. Friedman’s Prelude Therapeutics (PRLD) stock options expire?
These director stock options expire on June 8, 2036. After that expiration date, Friedman will no longer be able to exercise the options to purchase Prelude Therapeutics common stock at the $3.94 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates